Sangamo Therapeutics has been granted a patent for compositions containing non-naturally occurring zinc finger domains, fusion proteins, polynucleotides, and cells for treating or preventing Huntington’s Disease by modifying the Htt gene. The patent also covers an mRNA encoding a fusion protein with specific zinc finger domains that bind to the mutant Huntington’s gene allele. GlobalData’s report on Sangamo Therapeutics gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData

Report-cover

Data Insights Sangamo Therapeutics Inc - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Sangamo Therapeutics, Zinc-finger nucleases was a key innovation area identified from patents. Sangamo Therapeutics's grant share as of September 2023 was 46%. Grant share is based on the ratio of number of grants to total number of patents.

Patent granted for modifying htt gene to treat huntington's disease

Source: United States Patent and Trademark Office (USPTO). Credit: Sangamo Therapeutics Inc

A recently granted patent (Publication Number: US11723952B2) discloses an mRNA encoding a fusion protein that can modify the expression of the mutant Huntington's gene allele (mHtt) gene. The fusion protein consists of a transcriptional repression domain and a non-naturally occurring zinc finger protein with 5 or 6 zinc finger domains. The zinc finger protein specifically binds to sequences within the CAG repeat region of the mHtt gene.

The patent also covers the use of this mRNA in various applications. It describes a method of modifying the expression of the mHtt gene in a cell by administering one or more polynucleotides encoding the mRNA. This method can be used to potentially treat Huntington's Disease, a neurodegenerative disorder caused by the mutant Huntington's gene.

Furthermore, the patent claims a pharmaceutical composition comprising the mRNA, which can be administered to a subject in need of treatment for Huntington's Disease. The composition can be administered directly to the striatum, a region of the brain affected by the disease.

Overall, this patent provides a novel approach to modifying the expression of the mutant Huntington's gene allele using a fusion protein encoded by mRNA. The methods and compositions described in the patent have potential applications in the treatment of Huntington's Disease. However, it is important to note that the patent does not provide any experimental data or clinical trial results to support the efficacy of the described methods and compositions. Further research and testing would be required to validate the claims made in the patent.

To know more about GlobalData’s detailed insights on Sangamo Therapeutics, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies